Cellular Biomedicine Opens Shanghai CAR-T Facility

Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park . The company now has three China plants ( Beijing , Shanghai , Wuxi ), which will provide clinical trial supplies of its CAR-T candidate. In 2015, Cellular Biomedicine formed a partnership with the Chinese PLA General Hospital (the 301 hospital) of Beijing for the CAR-T immunotherapy. CBMG says it now has the ability to produce all plasmids and viral vectors for the therapy in-house. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.